title: Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.
authors.forename: D L
authors.initials: DL
authors.lastname: White
authors.forename: L N
authors.initials: LN
authors.lastname: Eadie
authors.forename: V A
authors.initials: VA
authors.lastname: Saunders
authors.forename: D K
authors.initials: DK
authors.lastname: Hiwase
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
mesh_terms: D001549:Benzamides / Q000493:pharmacokinetics*; D004347:Drug Interactions; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D010879:Piperazines / Q000493:pharmacokinetics*; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics*; D054328:Proton Pump Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000493:pharmacokinetics*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D054328:Proton Pump Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib